A reply to "Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC".

Vikram Jairam, Pamela R Soulos, Cary P Gross, James B Yu, Henry S Park, Roy H Decker

Journal: Lung cancer (Amsterdam, Netherlands) 2022;168():84-85

PMID: 34933760

Full Text on Elsevier Science View on PubMed

Abstract

Address: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, United States; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, United States. Electronic address: [email protected].; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, United States.; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, United States; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States; National Clinician Scholars Program, Yale University School of Medicine, New Haven, CT, United States.; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, United States; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, United States.

DOI: 10.1016/j.lungcan.2021.12.003

Link outs

Free resources

Medical:

https://medlineplus.gov/lungcancer.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-CALR-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Radiotherapy, Conformal, Radiotherapy, Intensity-Modulated